CPT code 91319 identifies a SARS–CoV–2 vaccine product (tris–sucrose formulation) supplied as a 10 mcg/0.3 mL intramuscular dose. As a vaccine product code, 91319 is used to denote the vaccine itself in billing and supply chains and is distinct from administration procedure codes. This code matters nationally because COVID–19 vaccination remains a core public health measure with wide-ranging payer coverage, supply tracking implications, and reporting requirements.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the clinical product and service context, a summary of typical sites of service, and an overview of payer relevance. The publication outlines where this product code fits in billing workflows, highlights common modifiers associated with vaccine billing (listed separately), and identifies missing input fields where applicable. Policy updates, reimbursement benchmarks, and clinical implications relevant to national vaccination programs are summarized to provide context for providers, billing staff, and policymakers.

Data not available in the input: associated taxonomies, ICD-10 diagnoses, related procedure codes, service line details, and payer-specific reimbursement rates.